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Abstract
Introduction: Macrophages/microglial cells are considered as immune cells in the central nervous system. Interleukin (IL)-16
is a proinflammatory cytokine produced by activated monocytic cells.
Materials and Methods: Expression of IL-16 was analyzed by immunohistochemistry in human astrocytic brain tumors and the
rat C6 glioblastoma tumor model. IL-16 was detected in both human astrocytic brain tumors and rat C6 glioma. 
Results:  Compared with human control brains, a significant increase in the percentages of parenchymal IL-16+
macrophages/microglia was observed already in grade II astrocytomas, indicating that IL-16+ immunostaining could be
a descriptor of a macrophage/microglia subset in astrocytic brain tumors. A further increase was observed at the transition
from grade II to III astrocytomas. This increase in IL-16 immunoreactivity correlated with WHO grades of human astrocyt-
ic brain tumors. 
Conclusions: Therefore, IL-16 might be a so far unknown factor in the regulation of the local inflammatory milieu of human
and experimental astrocytomas.
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ORIGINAL ARTICLE
INTRODUCTION
Macrophages/microglial cells constitute the first line
of cellular defense against a variety of stressors to the
central nervous system (CNS), participating in the regu-
lation of innate and adaptive immune responses in
human and rat gliomas [1]. Under neuropathological
conditions, microglia are activated, and activated
microglia are characterized morphologically by a grad-
ual transition from a quiescent stellate form to
a macrophage-like morphology, which is accompanied
by upregulation of surface antigens and the formation of
cell clusters. Recent studies indicate that activated
microglial cells occur not only within and around brain
tumors, but also contribute significantly to the actual
tumor mass, notably in astrocytic gliomas [16]. However,
their role in the pathogenesis of malignant brain tumor
progression remains unclear. A better understanding of
microglia-tumor interaction might be helpful in increas-
ing the therapeutic efficacy of future immune modula-
tory approaches. As we know, several regulatory factors
are secreted by activated microglia. It needs to be estab-
lished whether such activation-associated peptides can
be used to investigate microglial activation in gliomas of
different WHO grade.
Interleukin (IL)-16 is one of the candidates
expressed by activated monocytic cells. IL-16, known as
lymphocyte chemoattractant factor (LCF), serves asa natural soluble ligand for CD4 that contributes to the
regulatory process of CD4+ cell recruitment and activa-
tion at sites of inflammation in association with asthm
a and several autoimmune diseases. Thus it is consid-
ered a proinflammatory cytokine produced by a variety
of cells, including microglia [4, 5, 7, 14, 19]. In the
human brain, IL-16 is constitutively but minimally
expressed by a subpopulation of microglial cells [20]. In
the chronic inflammatory milieu of multiple sclerosis
lesions, IL-16 has been associated with the attraction of
CD4+ lymphocytes across the blood-brain barrier
(BBB) [21]. We showed previously that IL-16 is
expressed by inflammatory cells in non-malignant CNS
pathologies [9, 12, 24] as well as in human glioma [8].
Here we further describe the distribution of IL-16+ cells
in different human astrocytomas, including protoplas-
matic astrocytomas (WHO grade II), fibrillary astrocy-
tomas (WHO grade II), anaplastic astrocytomas (WHO
grade III), glioblastoma multiforme (WHO grade IV),
and four neuropathologically unaltered control brains.




Control brains without neuropathological alter-
ations were obtained from an established normal tissue
brain bank of the Institute of Brain Research of the
University of Tuebingen as published previously [20].
Autopsy data of these cases are listed in Table 1. We
investigated 50 primary brain tumor specimens, consist-
ing of 3 protoplasmatic astrocytomas (WHO grade II),
21 fibrillary astrocytomas (WHO grade II), 7 anaplastic
astrocytomas (WHO grade III), and 19 glioblastoma
multiforme (WHO grade IV; Table 2). The ages of the
patients (19 females and 31 males) ranged 20–77 years.
All tumor specimens were obtained before either radio-
therapy or chemotherapy. Histological grading of the
human tumor specimens was performed according to
the revised WHO classification guidelines [15]. Tumors
were resected at the Department of Neurosurgery at
Tuebingen.
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Table 1. Control brains
Patient no. Age  Gender Cause of death
(years)
1 49 F Respiratory and cardiac 
insufficiency
2 54 M Cardiopulmonary decom-
pensation
3 32 M Unclear cause of death
4 72 M Fulminant pulmonary 
embolism
F – female patient, M – male patient.
Table 2. Data of patients with different astrocytomas
Case Age Gender WHO Diagnosis
1 77 F IV GBM
2 20 F IV GBM
3 62 F IV GBM
4 77 M IV GBM
5 49 M IV GBM
6 65 F IV GBM
7 54 M IV GBM
8 48 M IV GBM
9 54 F IV GBM
10 72 M IV GBM
11 30 M IV GBM
12 71 M IV GBM
13 77 F IV GBM
14 69 M IV GBM
15 65 M IV GBM
16 65 M IV GBM
17 52 F IV GBM
18 71 F IV GBM
19 73 M IV GBM
20 73 M III ANA
21 63 M III ANA
22 56 M III ANA
23 42 M III ANA
24 39 F III ANA
25 28 M III ANA
26 71 F III ANA
27 31 F II FA
28 48 F II FA
29 29 M II FA
30 38 M II PRO
31 39 M II FA
32 68 M II FA
33 47 F II FA
34 30 M II FA
35 58 M II FA
36 28 M II PRO
37 38 F II PRO
38 32 F II FA
39 36 M II FA
40 48 M II FA
41 34 M II FA
42 57 F II FA
43 33 M II FA
44 42 M II FA
45 71 M II FA
46 45 F II FA
47 64 F II FA
48 30 F II FA
49 47 M II FA
50 63 M II FA
F – female patient, M – male patient, GBM – glioblastoma
multiforme, ANA – anaplastic astrocytoma, PRO – proto-
plasmatic astrocytoma, FA – fibrillary astrocytoma.Animal model
The rat C6 glioblastoma cell line was obtained from
the American Type Culture Collection (ATCC,
Manassas, VA, USA) and cultured in RPMI 1640 medi-
um with Glutamax II (Gibco, BRL, Paisely, UK) con-
taining 10% fetal calf serum (Gibco BRL) and 1.2%
penicillin/streptomycin (Fluka, Buchs, Switzerland) at
37°C and 5% CO2. C6 glioma cells were implanted as
follows: 15 male Sprague-Dawley rats (220–280 g,
Charles River, Sulzfeld, Germany) were anesthetized by
intraperitoneal injection of Ketanest (Ketamine-
hydrochloride, Parke Davis, USA; 100 mg/kg) and
Rompun (Xylazine-hydrochloride, Bayer, Germany; 10
mg/kg). In order to avoid xerophthalmia during anes-
thesia, the eyes were covered with Oculotect Gel
(Retinolpalmitate, CIBA Vision, Novartis, Germany).
After reaching an adequate depth of anesthesia, the skin
of the head was shaved, cleaned, and disinfected with
75% ethanol and incised (midline incision) to expose
the skull. After drilling a 2-mm hole 3 mm to the right
and 3 mm posterior to bregma, the rat was fixed in
a stereotactic apparatus (ASI Instruments, Germany).
The needle of an Hamilton syringe (900 series;
Hamilton Company, Reno, NV, USA) was inserted 4
mm from the pial surface vertically into the brain. Five
µl of C6 glioblastoma cell suspension (2×105 cells/µl)
were injected. Thereafter the needle was slowly with-
drawn and the skin was restored with a suture (4/0, FS-2,
Ethicon; Johnson & Johnson, Brussels, Belgium). After
two weeks the rats were sacrificed and perfused intrac-
ardially with fixative (4% formalin in 0.1 M phosphate-
buffered saline, pH 7.5). Four normal rats (without suf-
fering sham injection) were used as controls. All rats
were kept under controlled conditions of temperature
and light, with food and water available ad libitum. The
animals were cared for in accordance with published
International Health Guidelines under a protocol
approved by the local Institutional Animal Care and the
Administration District Official Committee.
Immunohistochemistry
Tissue samples were fixed in buffered 4% formalin
(pH 7.4) and paraffin-embedded by routine methods.
After dewaxing, sections (3 µm) were immersed in 0.01
M citrate buffer and irradiated for 15 min in
a microwave oven set at 600 W to enhance the fraction
of accessible epitopes. Endogenous peroxidase was
blocked with 1% H2O2 in methanol (15 min). Non-spe-
cific protein binding was inhibited by incubation with
normal porcine serum (Biochrom, Berlin, Germany) for
15 min. Tissue sections were incubated with purified
mouse anti-IL-16 monoclonal antibody (BMA, Augst,
Switzerland; diluted at 1:100 in TBS-BSA) overnight at
4°C. Specific antibody binding was detected by incubat-
ing the sections with a secondary biotinylated rabbit
anti-mouse IgG F(ab)2 antibody fragment (1:400; Dako,
Hamburg, Germany) for 30 min, followed by incubation
with a peroxidase-conjugated streptavidin-biotin-com-
plex (Dako). Labeled antigens were visualized by appli-
cation of 3,3’-diaminobenzidine (DAB; Fluka, Neu-
-Ulm, Germany) as a chromogen. All sections were
counterstained with Mayer’s Hemalaun.
Negative controls consisted of sections incubated in
the absence of the primary antibody. The specificity of
monoclonal IL-16 antibody was analyzed by isotype con-
trol and by preincubation of the monoclonal antibody
with an irrelevant cytokine, EMAP II (endothelial-
-monocyte activation polypeptide II) [22]. As a positive
control for IL-16 immunoreactivity we used rat and
human spleen sections, as macrophages are abundantly
found in this organ.
Double-labeling experiments
Double-labeling experiments were performed on
human tissues of GBM and rat C6 glioma. Antibodies
used for GBM included monoclonal antibody against
CD68 (clone KP-1, diluted 1:100 in TBS-BSA, Dako)
for microglia/macrophage identification. Activated
microglia/macrophages were detected with antibodies
directed against HLA-DR, -DP, and -DQ (MHC class
II, clone CR3/43, 1:50, Dako). Lymphocytic subsets
were typed by monoclonal antibodies against CD4 (T-
-helper lymphocytes, clone 1F6, 1:10, Dako) and CD3
(pan-T-cell marker, clone PS1, 1:100, Novocastra,
Dossenheim, Germany) and were applied overnight to
tissue sections at 4°C. For rat C6 glioma, sections were
incubated with monoclonal antibodies against ED1
(1:100; clone ED1, BMA, Augst, Switzerland) to
demonstrate activated microglia/macrophages. Briefly,
sections were dewaxed, irradiated in a microwave oven
for antigen retrieval, and incubated with porcine serum
as described above. Visualization was achieved by
adding biotinylated secondary rabbit anti-mouse IgG
diluted 1:400 for 30 min and alkaline phosphatase-con-
jugated ABC complex/AP (Dako, Kenmark) (1:400 in
TBS-BSA) for 30 min. The sections were developed
with Fast Blue BB salt (Fluka, Buchs, Switzerland),
yielding a blue reaction product. To avoid cross-reactiv-
ity, the probes were irradiated again in a microwave
oven. After administration of porcine serum for 15 min,
the sections were labeled with IL-16 antibody as already
described. Bound antibodies were visualized with DAB
(brown).
Evaluation of human astrocytomas and rat C6 gliomas
IL-16+ cells with the typical morphology of activated
microglial cells and with a clearly visible nucleus and all
counterstained cells with a visible nucleus were counted
in 10 high-power fields (×200 magnification with an eye-
piece grid representing 0.25 mm2) in 10 independent
areas of the tumor tissue for each section. The ratio of
positively labeled and counterstained nuclei was calcu-
lated in each brain tumor specimen and the control brain
section to obtain the percentage distribution of labeled
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against the outer vessel wall and cells in perivascular
spaces) were counted per 10 vessels and considered to be
positive if a minimum of two IL-16+ cells were present.
Statistical analysis
In order to stabilize variances, percentages were sub-
jected to an arcsine transformation before a one way
analysis of variance (Anova) was performed.
Differences of means were compared by a Tukey’s hon-
est significant difference post-hoc test. Data are pre-
sented as means and their 95% confidence intervals
(95%CI) after back-transformation. The percentages of
IL-16+ perivascular cells were calculated as means of
labeled perivascular cells (MLPVC). Data of the densi-
ty of IL-16+ parenchymal cells were calculated as means
of labeled parenchymal cells (MLPC).
RESULTS
Human control brains and astrocytomas
In four human control brains with no neuropatho-
logical alterations, IL-16 immunoreactivity was detected
in single microglia/macrophages. Only a few IL-16+ cells
were detected in perivascular spaces (Fig. 1A). 
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Fig. 1. Single immunohistochemical staining of IL-16 in control human brain (A), WHO Grade II fibrillary astrocytoma (B), WHO Grade
III anaplastic astrocytoma (C), and WHO Grade IV glioblastoma (D). Arrows indicate IL-16+ cells. In the glioma, double-labelling of IL-16
(brown) with CD68 (blue) confirms that macrophages are labelled with antibody against IL-16 (E). Double-labelling of IL-16 (brown) with
MHC-II (blue) (F). Double-labelling of IL-16 (brown) with CD4 (blue) (G). Double-labelling of IL-16 (brown) with CD3 (blue) (H). A–D:
×200; E–H: ×400.In human astrocytomas, the percentages of IL-16+
perivascular cells increased by a gradient from fibrillary
(MLPVC: 11.3%, 95%CI: 4.9–19.8%, WHO grade II) to
anaplastic astrocytomas (MLPVC: 77.0%, 95%CI:
57.9–91.5%, WHO grade III). In control brains
(MLPVC: 9.4%, 95%CI: 0.2–30.4%), protoplasmatic
astrocytomas (MLPVC: 13.0%, 95%CI: 0.3–39.8%),
and fibrillary astrocytomas (mentioned above; Fig. 2A),
no significant differences were observed between each
entity. There was also no significant difference between
anaplastic astrocytomas and glioblastomas multiforme
(MLPVC: 84.3%, 95%CI: 74.3–92.2%).
Changes in the percentage of IL-16+ cells occurring
in the brain parenchyma paralleled increased accumula-
tion of IL-16+ cells in perivascular spaces. In detail, IL-
-16+ cell numbers increased significantly in the brain
parenchyma ofcontrol brains (Fig. 1A, MLPC: 2.1%,
95%CI: 0.1–6.6%) to fibrillary astrocytomas (Fig. 1B,
MLPC: 7.4%, 95%CI: 5.1–10.3%) and further to
anaplastic astrocytomas (Fig. 1C, MLPC: 20.9%,
95%CI: 14.4–28.3%). In protoplasmatic astrocytomas
(MLPC: 8.9%, 95%CI: 2.9–17.7%) and glioblastomas
(Fig. 2D, MLPC: 24.4%, 95%CI: 20.0–29.1%), large
numbers of IL-16+ cells were observed (Fig. 2B). The
necrotic areas mainly contained cell debris and only very
rare IL-16+ macrophages/microglial cells. Abundant
labeling by IL-16 monoclonal antibody was observed in
tumor cells and TAMs adjacent to infiltration areas
(Fig. 1C and D). In the tumor parenchyma, the propor-
tion of stained cells varied considerably between differ-
ent areas of the tumor, especially in glioblastomas.
Double-labeling experiments revealed that the major
contributors of IL-16 expression were CD68+/IL-16+ cells
predominantly located at areas of infiltrative tumor growth
and in perivascular spaces (Fig. 1E). Co-localization of IL-
-16 and MHC-II molecules was frequently seen (Fig. 1F).
At the same time, only very few cells in glioblastoma were
characterized as CD4+/IL-16+ and/or CD3+/IL-16+ T lym-
phocytes (Fig. 1G and H, respectively).
IL-16 expression in normal rat brain and C6 gliomas
In contrast to human control brains, the four normal
rodent control brains revealed no perivascular
(MLPVC: 0.0%, 95%CI: 0–0.8%) and parenchymal IL-
-16+ cells (MLPC: 0.0%, 95%CI: 0–0.04%; Fig. 3A).
In rat C6 glioblastomas, massive IL-16 staining was
seen in areas of both compact tumor and tumor infiltra-
tion (Fig. 3B). Activated IL-16+ macrophages/microglial
phenotypes exhibiting retracted elongations/processes
were confined to perivascular spaces and regions of
infiltrative tumor growth (Fig. 3B and C, respectively).
In perivascular regions of rat C6 transplanted tumors,
IL-16+ cells accumulated in perivascular spaces
(MLPVC: 98.6%, 95%CI: 97.3–99.5%). In peritumoral
regions, the majority of IL-16+ cells were identified as
activated macrophages/microglial cells with long thin
protrusions/elongations, which was confirmed by
ED1+/IL-16+ staining (Fig. 3D). In control, in normal
rat brains (MLPC: 0.0%, 95%CI: 0–0.04%), opposing
hemispheres (MLPC: 0.0%, 95%CI: 0–0.01%), or
necrotic tumor lesion sites (MLPC: 0.0%, 95%CI:
0–0.01%), only single IL-16-labeled cells were
detectable, whereas the numbers of IL-16+ cells
increased significantly in peritumoral (MLPC: 21.0%,
95%CI: 20.2–21.8%) and infiltration areas (MLPC:
28.9%, 95%CI: 28.0–29.8%). 
DISCUSSION
Microglia/macrophages actively participate in the
immune response in human and rodent gliomas [1, 10].
The mechanisms of the activation of TAMs are still under
investigation. Here we report that IL-16was expressed on
macrophages/microglial cells in human and rat astrocytic
brain tumors of distinct tumor grades. In the present
study we found a positive correlation between the num-
bers of IL-16+ cells and glioma WHO grades.
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Fig. 2. Statistical evaluation of the distributions of IL-16+ cells in parenchyma sections (A) and in perivascular areas (B) in astrocytomas of
different malignancies. C – control brain; PRO – protoplasmatic astrocytoma (WHO grade II); FA – fibrillary astrocytoma (WHO grade II);
ANA – anaplastic astrocytoma (WHO grade III); GBM – glioblastoma multiforme (WHO grade IV).Inflammation occurs in most precancerous and can-
cerous tissues with pronounced infiltration of innate
immune cells like microglia and the production of spe-
cific inflammatory signaling molecules, including vari-
ous cytokines and chemokines [2, 3, 6, 18]. It has been
reported that in inflammatory conditions, IL-16 triggers
1) the generation of inositol trisphosphate, 2) transloca-
tion of protein kinase C, 3) the expression of proinflam-
matory cytokines (e.g. IL-6 and TNF-α) and growth fac-
tors (e.g. TGF-β) [7, 21], and 4) an increase in intracel-
lular Ca2+ levels, which can elicit the activation of
macrophages and control various microglial cell func-
tions [13, 17]. The role of IL-16 in brain tumors is
unclear so far. In the present study we observed the
expression of IL-16 on TAMs in both human and rat
astrocytic brain tumors. It has been reported that IL-16
plays a chemoattractant and immunomodulatory role in
CNS diseases [7]. In the present study we observed that
IL-16+ microglia/macrophages accumulated in perivas-
cular spaces of rat C6 tumors [26]. This suggests that this
cytokine might have the ability to promote the infiltra-
tion of large numbers of monocytes and lower number
of lymphocytes into the tumor, which could be in line
with the CD4+/IL-16+ and/or CD3+/IL-16+ T cells
observed in the present study. Therefore, IL-16+ TAMs
might contribute to the local inflammatory response and
the release of various factors supports tumor growth and
progression [6].
In the current study the correlation of IL-16+
macrophages/microglia with glioma WHO grading of
human astrocytic brain tumors was striking. Activation
of TAMs was suggested by coexpression of IL-16 and
CD-68 or MHC II antigen, which are up-regulated by
activated microglia present in CNS lesions. Conceding
a heterogeneous population of macrophages/microglial
cells, IL-16 in the present study might define a specific
subpopulation of activated microglial cell in brain tumor
pathology. Furthermore, IL-16 is a potent inducer of
TNF-α and IL-1β expression, both of which can increase
vascular permeability. Perivascular spaces are of partic-
ular neuroimmunological interest as they are prime por-
tals of monocyte transmigration and lymphocyte
drainage [11]. Expression of IL-16 by TAMs suggests
that IL-16 might have autocrine functions on microglial
cells. A paracrine mechanism of macrophage recruit-
ment based on IL-16 and CD4, which are weakly
expressed by monocytes, appears feasible. While TAMs
are capable of causing tumor cytotoxicity [10], paradox-
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Fig. 3. Single-labelling of IL-16 in rat brain sections. In normal rat brain, IL-16 staining was hardly seen (A). In rats with implanted C6
glioma, IL-16+ cells were strikingly located in areas of tumor mass (B); in the tumor infiltration areas, IL-16+ cells were especially concen-
trated in perivascular areas (C). Double-staining of IL-16+ cells (brown) with ED1 (blue) in the tumor infiltration of C6 glioma revealed
these cells as microglia/macrophages (arrows). A–C: ×200; D: ×400ically they can stimulate tumor growth by the secretion
of growth-inducing factors and angiogenic mediators
[23, 25]. The mechanism of malignancy-associated
macrophage recruitment is of further interest, as the
migratory pathways across the BBB might be exploited
in the development of novel tumor-homing therapeutic
agents.
In conclusion, IL-16 immunoreactivity is a putative
marker of a monocytic subset in human and rat gliomas
in vivo. Furthermore, upregulation of IL-16 expression
by this cell subset correlates with malignancy of tumors.
Therefore, IL-16 might be a novel factor in the regula-
tion of the local inflammatory milieu and tumor pro-
gression in both clinical and experimental astrocy-
toma/glioma.
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